Chartwell Investment Partners’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Chartwell Investment Partners’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-81,580	Closed	-$4.27M	–	474
2018 Q3	$4.27M	Buy	81,580 +113	+0.1%	+$6.16K	0.13%	243
2018 Q2	$3.54M	Sell	81,467 -3,105	-4%	-$133K	0.11%	260
2018 Q1	$3.13M	Sell	84,572 -1,833	-2%	-$48.9K	0.11%	234
2017 Q4	$1.71M	Sell	86,405 -6,153	-7%	-$132K	0.06%	346
2017 Q3	$2.3M	Buy	92,558 +4,388	+5%	+$81K	0.08%	308
2017 Q2	$1.54M	Buy	+88,170	New	+$1.54M	0.06%	321

Other funds holding GTHX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Chartwell Investment Partners's GTHX Position: Q4 2018 in Review

Chartwell Investment Partners sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2018, closing a stake of 81,580 shares — an estimated $4.27M sold.

Chartwell Investment Partners first reported a position in GTHX in Q2 2017 and held it in 6 quarters. The position peaked at $4.27M in Q3 2018. 93 funds tracked by Wall St. Rank hold GTHX as of Q4 2018.

Chartwell Investment Partners reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Chartwell Investment Partners sold 81,580 G1 Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $4.27M.
Chartwell Investment Partners first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 6 quarters.
Chartwell Investment Partners's G1 Therapeutics, Inc. Common Stock position peaked at $4.27M in Q3 2018.
93 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Chartwell Investment Partners's 13F filing for Q4 2018, filed 1 Feb 2019.